Health Canada has given Filament Health authorisation to carry out a Phase 2 clinical trial investigating PEX010 – the company’s botanical psilocybin drug candidate – for...
MIND Foundation’s INSIGHT Conference took place from August 31 to September 3 in Berlin, exploring the latest frontiers in psychedelic medicines – from clinical developments to...
New research has revealed that MDMA and methamphetamine deepen personal connections following guided conversations, and suggests different mechanisms for how these drugs produce feelings of closeness.
A team of researchers has analysed the experience of people with Obsessive-Compulsive Disorder (OCD) who have taken psychedelics, finding 30% experienced relief from their symptoms.
Results from a new analysis have revealed an improvement in mental health and cognition for Special Operations Forces veterans following a combination of psychedelic treatments.
Results from a major clinical trial have shown that esketamine outperforms one of the standard treatments for treatment-resistant major depression disorder (MDD).
Researchers from the University of Southern Denmark have established a psilocybin microdosing regimen in rats to help advance microdosing research.
Psychedelics have specific drug actions, such as inducing structural and functional neural plasticity, that could potentially treat mental health conditions and impact diseases affecting the brain,...
Therapist Jo Dice discusses some key points that you may want to know before taking psychedelics.
Dr Peter Sjöstedt-Hughes, Lecturer at Exeter University, has proposed incorporating metaphysical philosophy into psychedelic therapy to help improve therapeutic outcomes.
Canada’s non-profit advocacy organisation TheraPsil has announced the launch of its MDMA-assisted psychotherapy training programme.
Small Pharma has reported positive results from its study investigating the interaction of SSRIs and SPL026 – the company’s native DMT – in patients with Major...